Key result
Higher levels of serum sST2 and cfDNA were associated with increased LVEDd, LVESd, and E/A ratio, a lower likelihood of improvement, and a higher likelihood of 6-month readmission.
Why the study?
The study aimed to explore the significance of serum sST2 and circulating cfDNA in predicting cardiac functions in children with severe pneumonia complicated by myocardial damage.
Do serum sST2 and cfDNA levels predict cardiac function and outcomes in children with severe pneumonia complicated by myocardial damage?
Observational (n=60)
Do serum sST2 and cfDNA levels predict cardiac function and outcomes in children with severe pneumonia complicated by myocardial damage?
Elevated serum sST2 and cfDNA levels may serve as useful biomarkers for predicting adverse cardiac remodeling and readmission in children with severe pneumonia and myocardial damage.
Answers are grounded in this paper and cite their sources.
May support prognostic assessment in children with pneumonia-related myocardial injury; hypothesis-generating and requires prospective validation before clinical use.
Background: The paper aimed to explore the significance of serum soluble ST2 (sST2) and circulating cell-free DNA (cfDNA) in predicting cardiac functions in children with severe pneumonia complicated by myocardial damage. Methods: This case series study evaluated the serum sST2 and cfDNA levels of 60 children with severe pneumonia complicated by myocardial damage, assessing clinical data, biomarker levels, and cardiac function. Results: We analyzed data from a cohort of 60 patients with a mean age of 4.47±1.88 years and a male: female ratio of 28:32. At baseline, patients had elevated levels of serum biomarkers, including sST2 and cfDNA, which were associated with cardiac function parameters and clinical outcomes. After 6 months, patients showed significant correlations between sST2, cfDNA, and cardiac function parameters, including left ventricular end-diastolic diameter (LVEDd), left ventricular end-systolic diameter (LVESd), and E/A ratio. Multivariate analysis revealed that higher levels of sST2 and cfDNA were associated with increased LVEDd, LVESd, and E/A ratio, as well as a lower likelihood of improvement and a higher likelihood of 6-month readmission. Conclusions: These findings suggest that sST2 and cfDNA may be useful biomarkers for predicting cardiac function and outcomes in this patient population.
No takes yet. Share an insight, caveat, or question.
Tingting Zhao (2024) conducted an observational in severe pneumonia complicated by myocardial damage (n=60). Serum sST2 and cfDNA levels was evaluated on Cardiac function parameters (LVEDd, LVESd, E/A ratio) and clinical outcomes (improvement, 6-month readmission). Higher levels of serum sST2 and cfDNA were associated with increased LVEDd, LVESd, and E/A ratio, a lower likelihood of improvement, and a higher likelihood of 6-month readmission.
Synapse has enriched 10 related papers. Consider them for comparative context: